Want Cheaper Prescriptions for Your Staff? The Fight Over 'Optimized Sourcing'

The Bottom Line

If your company is self-insured, you probably rely on a Pharmacy Benefit Manager (PBM) to handle employee prescriptions—but they might be keeping you in the dark about cheaper alternatives like legal drug importation. This bill would force those middlemen to hand over unredacted drug cost data upon request and make it illegal for them to lie about the safety of alternative pharmacy programs. It's a major push to let Colorado employers shop around for better prescription prices without getting bullied.

What This Bill Actually Does

The world of Pharmacy Benefit Managers (PBMs) is notoriously murky. When an employer decides to self-insure its health plan, it usually hires a PBM or a health-care consultant to manage prescription drug claims and negotiate with drug companies. But what happens when that employer wants to bypass the PBM to save money—say, by using a prescription drug optimized sourcing program? These are lawful setups that often involve importing cheaper, FDA-approved medications from outside the United States. Right now, PBMs sometimes tell employers that these alternative programs are outright illegal or inherently unsafe, effectively killing the idea and keeping the employer's business for themselves.

HB26-1056—officially the Prescription Drug Optimized Sourcing Transparency and Integrity Act—creates strict new rules to level the playing field and stop that kind of interference. First, it explicitly prohibits PBMs and health-care consultants from knowingly spreading false or misleading information to employers about the legality or safety of alternative pharmacy stewardship programs. Second, it gives self-insured employers a powerful new tool: the right to demand detailed, unredacted cost data. Upon written request, PBMs must hand over the exact financial breakdown for every single drug dispensed under the plan, including the total cost per claim, the member-paid portion, the employer-paid portion, and the specific National Drug Code (NDC).

The bill goes out of its way to formally declare that these alternative sourcing programs—including personal-use importation programs authorized by federal law—are recognized, legal cost-containment tools in Colorado. To ensure these new transparency rules actually have teeth, the legislation categorizes any violation as a deceptive trade practice in the business of insurance. That means the state's Commissioner of Insurance gets the authority to step in, investigate, and penalize middlemen who refuse to share their data or try to scare employers away from cheaper drug pipelines.

What It Means for You

If you get your health insurance through a self-insured employer—which includes many mid-to-large companies, school districts, and local governments—this bill is ultimately about what you pay at the pharmacy counter. Right now, a huge chunk of your premium dollars and annual deductibles goes toward prescription drugs. Because your employer's Pharmacy Benefit Manager (PBM) largely controls the pricing and the approved drug list, there is a very good chance your company is overpaying for standard medications, which trickles down to your paycheck in the form of higher health premiums. This legislation empowers your employer to seek out cheaper alternatives without getting stonewalled by industry middlemen.

Let's talk about how this directly hits your wallet if your employer takes advantage of the new rules. If your company decides to use an alternative pharmacy stewardship program—like legally importing insulin or specialized daily medications from other countries—the bill requires that these programs maintain your patient safety, keep your therapy consistent, and guarantee an equal or lower member cost share. That means you wouldn't be forced to pay more out-of-pocket just because your boss found a cheaper wholesale pipeline. For any medications not covered by the alternative program, you would simply continue using your regular pharmacy card as usual.

From a consumer protection standpoint, this bill represents a massive shift in transparency. While you won't be the one personally requesting the data, your employer will finally have the legal right to see the exact total drug cost per claim and the total member-paid portion without any redactions or blacked-out numbers. When employers actually know what they are paying versus what you are paying, they are in a much better position to negotiate better health benefits, lower your monthly premiums, or at least stop the bleeding on double-digit annual health care cost hikes.

What It Means for Your Business

If you are a business owner or executive running a self-insured health plan, this legislation is built specifically for you. Controlling healthcare costs is consistently one of the biggest headaches for Colorado employers, and prescription drugs are often the most unpredictable expense on the balance sheet. Under current conditions, trying to audit your Pharmacy Benefit Manager (PBM) or health-care consultant can feel like pulling teeth. They frequently use confidentiality clauses, complex rebates, or claim "proprietary pricing" to hide the true spread between what they pay the pharmacy and what they charge you. This bill gives you a statutory crowbar to pry open that black box.

Here is what changes on the ground: If you decide to explore a prescription drug optimized sourcing program to save money, your PBM can no longer use scare tactics to keep you in their ecosystem. The bill makes it a deceptive trade practice for them to knowingly tell you that these alternative pipelines—such as federally compliant international drug importation—are illegal or inherently unsafe. More importantly, you gain the absolute legal right to submit a written request for detailed, unredacted claims data. Your PBM will be required by law to show you the National Drug Code (NDC), quantity, days of supply, and exactly how much of each claim was covered by the plan versus the employee. They cannot withhold, edit, or redact this information.

To prepare for this level of transparency, self-insured employers should start reviewing their current PBM and consultant contracts. Look closely at any clauses that currently restrict your right to audit claims data or carve out specific prescription programs. Because the law applies to conduct occurring after its effective date (slated for August 12, 2026, assuming the legislature adjourns on time and no voter petitions intervene), you will soon have significant leverage. You can use this data to renegotiate your pharmacy benefits or farm out a subset of expensive specialty drugs to a third-party stewardship program, potentially saving your company thousands of dollars per employee without reducing the quality of their care.

Follow the Money

Despite the bill including specific language directing the Department of Regulatory Agencies (DORA) to implement these new rules within "existing appropriations," the official legislative fiscal note tells a different story. State analysts project that Colorado will actually need to spend about $113,400 annually starting in the 2026-27 fiscal year to enforce these provisions. This money primarily covers 0.4 FTE at the Division of Insurance to field complaints from employers and investigate violations, plus about 500 hours of legal services from the Attorney General’s office to handle enforcement actions against non-compliant PBMs.

Because the Division of Insurance is funded by premium tax revenues that would otherwise naturally flow to the state's General Fund, this represents a $113,413 diversion from the General Fund each year. On the flip side, the state might see an unpredictable bump in cash revenue from civil penalties. Because violations are classified as deceptive trade practices, the state can levy fines of up to $3,000 per violation, with higher penalties for repeat or willful offenses. As for local governments and school districts that operate self-insured plans for their own employees, they won't see direct state costs but could realize significant operational savings if they leverage the new transparency rules to lower their own prescription drug spending.

Where This Bill Stands

HB26-1056 is currently Dead. The latest official action came on 02/17/2026: House Committee on Health & Human Services Postpone Indefinitely.

That means the bill is no longer advancing this session. In practice, measures that are postponed indefinitely or otherwise declared lost generally stay dead unless they are reintroduced in a future session.